
BioXcel touts healthy volunteer data for neuro therapy; Ionis, Chinook partner on rare kidney disease
BioXcel Therapeutics reported some new healthy volunteer data that it’s touting as positive.
The biotech said in a press release Tuesday that its experimental BXCL501 therapy as an adjunct for major depressive disorder proved safe and tolerable in a Phase Ib multiple-ascending dose trial, results that allow researchers to select a dose for Phase II. The maximum tolerated dose was not attained, CMO Robert Risinger said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.